ANDROGENETIC ALOPECIA: A REVIEW OF CURRENT THERAPEUTIC OPTIONS
DOI:
https://doi.org/10.31435/ijitss.4(48).2025.4291Keywords:
Androgenetic Alopecia, Minoxidil, Finasteride, Platelet-Rich Plasma, Hair TransplantationAbstract
Introduction: Androgenetic alopecia (AGA) is the most common form of hair loss, caused by a genetically determined hypersensitivity of hair follicles to dihydrotestosterone (DHT). This condition affects both sexes and significantly impacts quality of life.
Aim: The aim of this review is to present current and new therapeutic options for the treatment of androgenetic alopecia.
Methods: A literature review was conducted in PubMed, Scopus and Google Scholar databases from 2015 to 2025, covering 19 publications on pharmacotherapy, supportive and surgical methods.
Results: Minoxidil (topical and oral) and 5α-reductase inhibitors are the most effective methods. Adjunctive therapies such as platelet-rich plasma, microneedling, LLLT, and spironolactone enhance treatment efficacy. In advanced cases, hair transplantation techniques are the solution.
Conclusions: The treatment of AGA requires individualisation, combination therapy and long-term monitoring. The development of regenerative methods creates new therapeutic perspectives.
References
Aleissa M. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Cureus 2023;15:e43559. https://doi.org/10.7759/cureus.43559
Dhurat R, Sukesh M, Avhad G, Dandale A, Pal A, Pund P. A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study. Int J Trichology 2013;5:6–11. https://doi.org/10.4103/0974-7753.114700
Estill MC, Ford A, Omeira R, Rodman M. Finasteride and dutasteride for the treatment of male androgenetic alopecia: A review of efficacy and reproductive adverse effects. Georgetown Medical Review 2023;7. https://doi.org/10.52504/001c.88531
Gupta AK, Talukder M, Shemer A, Piraccini BM, Tosti A. Low-Dose Oral Minoxidil for Alopecia: A Comprehensive Review. Skin Appendage Disord 2023;9:423–37. https://doi.org/10.1159/000531890
Kaiser M, Abdin R, Gaumond SI, Issa NT, Jimenez JJ. Treatment of androgenetic alopecia: current guidance and unmet needs. Clin Cosmet Investig Dermatol 2023;16:1387–406. https://doi.org/10.2147/CCID.S385861
Ntshingila S, Oputu O, Arowolo AT, Khumalo NP. Androgenetic alopecia: An update. JAAD International 2023;13:150–8. https://doi.org/10.1016/j.jdin.2023.07.005
Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther 2019;13:2777–86. https://doi.org/10.2147/DDDT.S214907
Koralewicz MM, Szatkowska OA. Topical solutions for androgenetic alopecia: evaluating efficacy and safety. Forum Dermatologicum 2024;10:71–8. https://doi.org/10.5603/fd.101208
Kumar MK, Inamadar AC, Palit A. A Randomized Controlled, Single-Observer Blinded Study to Determine the Efficacy of Topical Minoxidil plus Microneedling versus Topical Minoxidil Alone in the Treatment of Androgenetic Alopecia. J Cutan Aesthet Surg 2018;11:211–6. https://doi.org/10.4103/JCAS.JCAS_130_17
Martínez-Pizarro S. Low-level laser therapy for androgenetic alopecia. Actas Dermo-Sifiliográficas (English Edition) 2021;112:99–102. https://doi.org/10.1016/j.adengl.2020.03.017
Müller Ramos P, Melo DF, Radwanski H, de Almeida RFC, Miot HA. Female-pattern hair loss: therapeutic update. An Bras Dermatol 2023;98:506–19. https://doi.org/10.1016/j.abd.2022.09.006
Penha MA, Miot HA, Kasprzak M, Müller Ramos P. Oral minoxidil vs topical minoxidil for male androgenetic alopecia: A randomized clinical trial. JAMA Dermatol 2024;160:600–5. https://doi.org/10.1001/jamadermatol.2024.0284
Pillai JK, Mysore V. Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia. J Cutan Aesthet Surg 2021;14:385–91. https://doi.org/10.4103/JCAS.JCAS_218_20
Razmi Tm, Subburaj K. Hair transplantation: A brief review. Clin Dermatol Rev 2022;6:80. https://doi.org/10.4103/cdr.cdr_76_21
Sereepanpanich V, Khunkhet S, Rojhirunsakool S, Udompataikul M. Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study. JAAD International 2025;23:69–76. https://doi.org/10.1016/j.jdin.2025.08.009
Shanshanwal SJS, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol 2017;83:47–54. https://doi.org/10.4103/0378-6323.188652
Sondagar DM, Mehta HH, Agharia RS, Jhavar MK. Efficacy of Low-Level Laser Therapy in Androgenetic Alopecia - A Randomized Controlled Trial. Int J Trichology 2023;15:25–32. https://doi.org/10.4103/ijt.ijt_5_22
Wang F, Chen Y, Yang C, Li C, Zhang H, He J, et al. Using the follicular unit extraction technique in treatment of male androgenetic alopecia. BMC Surg 2024;24:358. https://doi.org/10.1186/s12893-024-02655-1
Werachattawatchai P, Khunkhet S, Harnchoowong S, Lertphanichkul C. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study. Int J Womens Dermatol 2025;11:e227. https://doi.org/10.1097/JW9.0000000000000227
Downloads
Published
Issue
Section
License
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
